WX-0593 Combined With Concurrent Chemoradiotherapy in Unresectable Locally Advanced NSCLC

This study is testing a targeted drug called WX-0593 (an ALK/ROS1 inhibitor) given alongside standard chemoradiation for people with inoperable, locally advanced non-small cell lung cancer (NSCLC) whose tumors have specific gene mutations (ALK or ROS1). **You may be eligible if...** - You are 18 or older with a confirmed diagnosis of locally advanced, inoperable NSCLC (stage II–III) - Your tumor has an active ALK or ROS1 mutation - You have not received any prior treatment for this cancer - Your lung function, organ function, and performance status are within acceptable limits **You may NOT be eligible if...** - You have another cancer diagnosed within the past 5 years - Your tumor has mixed small cell and non-small cell features - You have previously received ALK-targeted therapy - You have significant interstitial lung disease or active tuberculosis - You have an active autoimmune disease - You are pregnant or breastfeeding Talk to your doctor to see if this trial is right for you.